Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Background: The prevalence of heart failure with mildly reduced or preserved ejection
fraction markedly increases with age, with older individuals disproportionately facing excess …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Background: Frailty may modify the risk− benefit profile of certain treatments, and frail
patients may have reduced tolerance to treatments. Objective: To investigate the efficacy of …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Background: Sodium-glucose cotransporter-2 inhibitors have emerged as a key
pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …